Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: A protocol for a multicenter, randomized, double-blind, placebo-controlled, phase 3 study (the SCORPIO-SR trial)
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Yuko Tsuge, Takeki Uehara, Hiroshi Mukae
doi: https://doi.org/10.1101/2022.07.15.22277670
Hiroshi Yotsuyanagi
1The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Norio Ohmagari
2Disease Control and Prevention Center, National Center for Global Health, Tokyo, Japan
Yohei Doi
3Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
4Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan
Takumi Imamura
5Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
Takuhiro Sonoyama
5Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
Genki Ichihashi
5Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
Takao Sanaki
6Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan
Yuko Tsuge
5Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
Takeki Uehara
5Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
Hiroshi Mukae
7Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

- supplemental table[supplements/277670_file02.pdf]
Posted July 17, 2022.
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: A protocol for a multicenter, randomized, double-blind, placebo-controlled, phase 3 study (the SCORPIO-SR trial)
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Yuko Tsuge, Takeki Uehara, Hiroshi Mukae
medRxiv 2022.07.15.22277670; doi: https://doi.org/10.1101/2022.07.15.22277670
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: A protocol for a multicenter, randomized, double-blind, placebo-controlled, phase 3 study (the SCORPIO-SR trial)
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Yuko Tsuge, Takeki Uehara, Hiroshi Mukae
medRxiv 2022.07.15.22277670; doi: https://doi.org/10.1101/2022.07.15.22277670
Subject Area
Subject Areas
- Addiction Medicine (227)
- Allergy and Immunology (500)
- Anesthesia (110)
- Cardiovascular Medicine (1226)
- Dermatology (147)
- Emergency Medicine (282)
- Epidemiology (9998)
- Gastroenterology (497)
- Genetic and Genomic Medicine (2441)
- Geriatric Medicine (236)
- Health Economics (479)
- Health Informatics (1634)
- Health Policy (750)
- Hematology (247)
- HIV/AIDS (530)
- Medical Education (251)
- Medical Ethics (74)
- Nephrology (267)
- Neurology (2271)
- Nursing (139)
- Nutrition (349)
- Oncology (1244)
- Ophthalmology (375)
- Orthopedics (133)
- Otolaryngology (226)
- Pain Medicine (154)
- Palliative Medicine (50)
- Pathology (324)
- Pediatrics (728)
- Primary Care Research (281)
- Public and Global Health (4822)
- Radiology and Imaging (833)
- Respiratory Medicine (650)
- Rheumatology (283)
- Sports Medicine (224)
- Surgery (266)
- Toxicology (44)
- Transplantation (124)
- Urology (99)